We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK, Impax Drug Shortens Parkinson’s ‘Off Time’ Versus Stalevo
GSK, Impax Drug Shortens Parkinson’s ‘Off Time’ Versus Stalevo
August 15, 2011
GlaxoSmithKline (GSK) and Impax Pharmaceuticals’ developmental Parkinson’s disease drug has again shown a longer efficacy window compared with a traditional treatment, paving the way for a fourth-quarter filing. However, analysts point out Novartis’ Stalevo will go generic by launch time, creating an obstacle to uptake.